Evidence map›Paper›PMID 38748319›Full record

Trial reportImmunologic research2024

Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses - a randomized, placebo-controlled clinical trial.

Boukje C Eveleens Maarse, Micha N Ronner, Manon A A Jansen, Tessa Niemeyer-van der Kolk, Aliede E In 't Veld, Erica S Klaassen, Saira Ahmad, Andrea Itano, Duncan McHale, Matthijs Moerland

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Immunologic research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Boukje C Eveleens MaarseCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Micha N RonnerCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Manon A A JansenCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Tessa Niemeyer-van der KolkCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Aliede E In 't VeldCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Erica S KlaassenCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands.
Saira AhmadEvelo Biosciences Inc., One Kendall Square, Building 600/700, Suite 7-201, Cambridge, MA, USA.
Andrea ItanoEvelo Biosciences Inc., One Kendall Square, Building 600/700, Suite 7-201, Cambridge, MA, USA.
Duncan McHaleEvelo Biosciences Inc., One Kendall Square, Building 600/700, Suite 7-201, Cambridge, MA, USA.
Matthijs MoerlandCentre for Human Drug Research, Zernikedreef 8, 2333 CL, Leiden, The Netherlands. mmoerland@chdr.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiome can modulate systemic inflammation and is therefore target for immunomodulation. Immunomodulating effects of EDP1815, a bacterial commensal strain of Prevotella histicola, were studied in healthy participants. Effects on adaptive immunity were evaluated by a neo-antigen challenge with keyhole limpet haemocyanin (KLH), while effects on innate immunity were evaluated by topical toll-like receptor 7 (TLR7) agonist imiquimod. Capsules with two enteric coating levels (EC1, EC2) were compared. Thirty-six healthy participants were included and received a daily dose of 8 × 10

Indexed as

Adaptive ImmunityImiquimodImmunity, InnateAdultCytokinesFemaleHemocyaninsHumansImmunomodulationMaleMiddle AgedSkinToll-Like Receptor 7Young AdultCytokinesHemocyaninsImiquimodkeyhole-limpet hemocyaninToll-Like Receptor 7Autoimmune diseasesImiquimod ImmunodermatologyImmune challengesKeyhole limpet haemocyaninMicrobiome

Identifiers

PMID38748319
PMCPMC11347467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.